JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

185.53 -1.88

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

183.42

Massimo

189.08

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.81% upside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.7B

10B

Apertura precedente

187.41

Chiusura precedente

185.53

Notizie sul Sentiment di mercato

By Acuity

50%

50%

144 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 feb 2026, 17:25 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 feb 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 feb 2026, 23:43 UTC

Discorsi di Mercato

Gold Falls on Possible Technical Correction -- Market Talk

9 feb 2026, 23:14 UTC

Discorsi di Mercato

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 feb 2026, 22:29 UTC

Discorsi di Mercato

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 feb 2026, 22:19 UTC

Discorsi di Mercato

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 feb 2026, 22:08 UTC

Discorsi di Mercato

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 feb 2026, 22:01 UTC

Utili

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 feb 2026, 21:59 UTC

Utili

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 feb 2026, 21:59 UTC

Utili

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 feb 2026, 21:58 UTC

Utili

Friedman Industries 3Q Sales $168M >FRD

9 feb 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

9 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 feb 2026, 21:48 UTC

Utili

Friedman Industries 3Q EPS 43c >FRD

9 feb 2026, 21:17 UTC

Utili

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 feb 2026, 21:13 UTC

Discorsi di Mercato

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 feb 2026, 21:04 UTC

Utili

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 feb 2026, 20:30 UTC

Discorsi di Mercato

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 feb 2026, 20:02 UTC

Discorsi di Mercato

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 feb 2026, 19:42 UTC

Discorsi di Mercato

Japan's Yield Curve Expected to Flatten -- Market Talk

9 feb 2026, 19:31 UTC

Discorsi di Mercato

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 feb 2026, 19:27 UTC

Discorsi di Mercato

Gold Climbs Back Over $5,000/oz -- Market Talk

9 feb 2026, 19:05 UTC

Discorsi di Mercato

Nike Returns to List of Hottest Brands -- Market Talk

9 feb 2026, 18:19 UTC

Discorsi di Mercato

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 feb 2026, 17:41 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 feb 2026, 17:31 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 feb 2026, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

9 feb 2026, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 feb 2026, 17:17 UTC

Discorsi di Mercato

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 feb 2026, 17:16 UTC

Utili

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

19.81% in crescita

Previsioni per 12 mesi

Media 226.7 USD  19.81%

Alto 265 USD

Basso 185 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

9

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

144 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat